RGCC CAMBISeq® is an innovative test that uses next-generation sequencing analysis on both DNA and RNA to provide clinicians with crucial insight into cancer.
The CAMBISeq® – or cancer analysis, mutational burden and instability sequencing – test is used to identify variants in 500 genes that our scientists use as biomarkers to assess their sensitivity to immunotherapy. The results can predict how well a patient will respond to types of immunotherapy.
RGCC CAMBISeq® is suitable for all patients who have a confirmed cancer diagnosis. The test can be used by clinicians to identify the best, and most effective, combinations of cancer treatments.